Stock Events

Stock Events

Addex Therapeutics 

0
13
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24AugExpected
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-22,346.57%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
32,094.96Revenue
-7.17MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow APE0.MU. It's not an investment recommendation.
Apple
2
AAPL
Amazon
2
AMZN
NVIDIA
2
NVDA
AMD
2
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap8.66B
Alkermes plc operates in the CNS therapeutic area, making it a direct competitor to Addex Therapeutics in developing treatments for neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap4.49B
ACADIA Pharmaceuticals specializes in CNS disorders, including Parkinson’s disease psychosis, directly competing with Addex's focus areas.
BridgeBio Pharma
BBIO
Mkt Cap16.82B
BridgeBio Pharma targets genetic diseases and cancers, including neurological disorders, overlapping with Addex Therapeutics' research focus.
Biogen
BIIB
Mkt Cap29.4B
Biogen is a major player in neurodegenerative diseases, Alzheimer's, and multiple sclerosis, competing in the CNS space.
AMGEN
AMGN
Mkt Cap196.12B
Amgen's broad focus on innovative therapeutics includes CNS disorders, positioning it as a competitor in the neurological space.
Palatin Technologies
PTN
Mkt Cap17.79M
Palatin Technologies works on developing therapeutics for diseases with a focus on CNS, making it a competitor in the neurological treatment market.
Novartis
NVS
Mkt Cap293.94B
Novartis has a diversified portfolio that includes treatments for neurological conditions, competing with Addex in the broader CNS therapeutic area.
Pfizer
PFE
Mkt Cap137.76B
Pfizer has a wide range of therapeutic areas, including CNS disorders, making it a competitor in developing treatments for neurological conditions.

About

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Show more...
CEO
Mr. Timothy Mark Dyer
Employees
3
Country
Switzerland
ISIN
US00654J1079

Listings

MU
DE
APE.MU
STU
DE
APE1.STU
MU
DE
APE0.MU
LSE
GB
0QNV.LSE

0 Comments

Share your thoughts

FAQ

What is Addex Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Addex Therapeutics stocks are traded under the ticker APE0.MU.
When is the next Addex Therapeutics earnings date?▼
Addex Therapeutics is going to release the next earnings report on August 24, 2026.
What is Addex Therapeutics revenue for the last year?▼
Addex Therapeutics revenue for the last year amounts to 32,094.96 EUR.
What is Addex Therapeutics net income for the last year?▼
APE0.MU net income for the last year is -7.17M EUR.
How many employees does Addex Therapeutics have?▼
As of August 09, 2026, the company has 3 employees.
In which sector is Addex Therapeutics located?▼
Addex Therapeutics operates in the Health & Wellness sector.
When did Addex Therapeutics complete a stock split?▼
The last stock split for Addex Therapeutics was on October 23, 2023 with a ratio of 1:20.
Where is Addex Therapeutics headquartered?▼
Addex Therapeutics is headquartered in Geneva, Switzerland.